Vanda Pharmaceuticals Comments on FDA’s Recently Announced Guidance on Communication with Health Care Professionals Regarding FDA-Approved Drugs

Posted on by

WASHINGTON, Jan. 12, 2024 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) submitted a comment letter (here) on January 5, 2024, regarding the FDA’s recently announced policy—by way of a draft guidance document—that substantially restricts drug manufacturers’ ability to…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.